Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The Dihexa + Cerebrolysin stack is an advanced neuroprotective combination for neuroplasticity and cognitive restoration. Dihexa is a HGF/c-Met receptor agonist reported to be millions of times more potent than BDNF at promoting synaptogenesis in animal models. Cerebrolysin is a porcine brain-derived peptide preparation containing neurotrophic factors used clinically for decades in Europe/Asia for stroke recovery, TBI, and cognitive decline. Together, Dihexa drives new synapse formation while Cerebrolysin provides neurotrophic support for neuronal survival and repair. This is an advanced/experimental stack due to limited human data on Dihexa.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) activates the HGF/c-Met receptor pathway, one of the most powerful drivers of synaptogenesis and dendritic spine formation. In animal models it restored cognitive function in aged rats and models of neurodegeneration. It promotes the formation of new synaptic connections at potencies far exceeding BDNF.
Cerebrolysin provides a balanced cocktail of neurotrophic factors, neuropeptides, and gangliosides that support neuronal survival, reduce apoptosis, and enhance synaptic plasticity. While Dihexa creates new synaptic connections, Cerebrolysin nourishes and protects both new and existing neurons. Clinical data supports its use in stroke recovery and Alzheimer disease.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Conservative | Dihexa 10mg oral daily | Cerebrolysin 5mL IM 5x/week | AM oral, AM IM | 4 weeks |
| Standard | Dihexa 20mg oral daily | Cerebrolysin 5mL IM 5x/week | AM | 4-8 weeks |
| Research | Dihexa 5mg SubQ daily | Cerebrolysin 10mL IM 5x/week | AM | 4 weeks on, 2 off |
| Panel | Markers | Timing |
|---|---|---|
| Basic | CBC, CMP | Baseline, Week 4 |
| Liver | ALT, AST, GGT | Baseline, Week 4 |
| Inflammatory | CRP | Baseline, Week 4 |
Liver monitoring important given experimental nature of dihexa. Consider formal cognitive testing to objectively measure improvements.
Dihexa has remarkable animal model results but very limited human safety data. The HGF/c-Met pathway is also involved in certain cancers, making cancer history a contraindication. Short cycling with breaks is recommended.
Cerebrolysin benefits persist 2-3 months after a course in clinical studies. Dihexa-driven synaptogenesis may create lasting changes if consolidated through cognitive engagement. Ongoing research needed for long-term data.
Dihexa drives new synapse formation through HGF/c-Met receptor activation. Cerebrolysin provides neurotrophic factors that support neuronal survival and synaptic plasticity. Together they create new neural connections and nourish existing ones.
Dihexa has remarkable animal model results but very limited human safety data. The HGF/c-Met pathway is also involved in certain cancers, making cancer history a contraindication. Short cycling with breaks is recommended.
Cerebrolysin benefits persist 2-3 months after a course in clinical studies. Dihexa-driven synaptogenesis may create lasting changes if consolidated through cognitive engagement. Ongoing research needed for long-term data.
Dihexa drives new synapse formation through HGF/c-Met receptor activation. Cerebrolysin provides neurotrophic factors that support neuronal survival and synaptic plasticity. Together they create new neural connections and nourish existing ones.
Dihexa has remarkable animal model results but very limited human safety data. The HGF/c-Met pathway is also involved in certain cancers, making cancer history a contraindication. Short cycling with breaks is recommended.
Cerebrolysin benefits persist 2-3 months after a course in clinical studies. Dihexa-driven synaptogenesis may create lasting changes if consolidated through cognitive engagement. Ongoing research needed for long-term data.